http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20210144365-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-136 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57419 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57484 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886 |
| filingDate | 2020-05-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20210144365-A |
| titleOfInvention | Age-specific biomarker of a patient with colorectal cancer and use thereof |
| abstract | The present invention relates to an age-specific biomarker for colorectal cancer patients and their use, and specifically, a platelet derived growth factor receptor alpha (PDGFRA) gene or a protein encoded by the gene for a subject under 40 years of age for colorectal cancer diagnosis or It relates to a method for predicting prognosis and a method for selecting an anticancer drug customized for colorectal cancer patients under 40 years of age. The expression of the PDGFRA gene according to the present invention was significantly increased in the low-age patient group under 40 years of age compared to the high-age colorectal cancer patient group, and even between the CMS4 type patient group with poor prognosis, it was significantly increased in the low-age patient group. The expression is increased, and it was confirmed that it is also associated with the expression of EMT and angiogenic factors. In addition, it was confirmed that cells (PDCs) derived from a patient group under 40 years of age exhibit sensitivity when the expression of PDGFRA is inhibited or treated with an anticancer agent that targets it. It can be used for diagnosis and prognosis prediction of colorectal cancer in the following subjects, and is also expected to be usefully used in determining a treatment strategy for selecting a customized anticancer agent for colorectal cancer patients of the above age group. |
| priorityDate | 2020-05-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 398.